Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
1 clinical trials · Condition
◉ Watch Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
| Record | Firm | Date |
|---|---|---|
| Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable (NCT05495724) | Tianjin Medical University Second Hospital | 2021-07-23 |
Track Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.